Therapeutic implications of leukemic stem cell pathways
Therapeutic implications of leukemic stem cell pathways
复制标题
DOI：
10.1158/1078-0432.ccr-07-1088
复制
发表时间：
2007-11-15
影响因子：
11.5
通讯作者：
Burger, Angelika M.
中科院分区：
文献类型：
--
作者：
Chumsri, Saranya;Matsui, William;Burger, Angelika M.
癌症生物学中的一个新兴概念是，在构成肿瘤的异质细胞群中存在罕见的癌症干细胞群。这个概念在人类髓性白血病中得到了最好的理解。正常和恶性造血干细胞的功能由一组共同的关键严厉性基因决定，这些基因调节自我更新和发育途径。一些严重度因子，如Notch或端粒酶，在正常造血干细胞和白血病干细胞中表现出不同的激活。这些差异可以被用于治疗，甚至是已经在临床用于治疗白血病的药物。然而，将新的和现有的白血病干细胞导向疗法转化为临床实践，将需要改变临床试验设计，并将干细胞生物标志物作为相关终点。
An emerging concept in cancer biology is that a rare population of cancer stem cells exists among the heterogeneous cell mass that constitutes a tumor. This concept is best understood in human myeloid leukemia. Normal and malignant hematopoietic stem cell functions are defined by a common set of critical sternness genes that regulate self-renewal and developmental pathways. Several sternness factors, such as Notch or telomerase, show differential activation in normal hematopoietic versus leukemia stem cells. These differences could be exploited therapeutically even with drugs that are already in clinical use for the treatment of leukemia. The translation of novel and existing leukemic stem cell-directed therapies into clinical practice, however, will require changes in clinical trial design and the inclusion of stem cell biomarkers as correlative end points.